Synopsis: Neogen Chemicals reported its Q4 and full-year FY26 audited results on May 16, 2026, showing solid standalone revenue growth and a recovery in profitability. However, the spotlight is on subsidiary Neogen Ionics Limited, whose Dahej and Pakhajan projects face revised timelines and swelling costs, raising fresh investor questions.
Neogen Chemicals Limited held its Board of Directors meeting on Saturday, May 16, 2026, approving the standalone and consolidated audited financial results for Q4 and the full financial year ended March 31, 2026. The statutory auditors, M/s. Chandabhoy & Jassoobhoy, Chartered Accountants, issued an unmodified opinion on both the standalone and consolidated results, providing clean regulatory compliance.
On the standalone front, Neogen delivered a strong revenue performance. Revenue from operations for FY26 stood at Rs. 855.49 crore, compared to Rs. 773.65 crore in FY25, reflecting a year-on-year growth of approximately 10.6%. For Q4 FY26 alone, revenue came in at Rs. 248.63 crore against Rs. 203.75 crore in Q4 FY25, a quarterly growth of over 22%. Total income for the full year reached Rs. 871.31 crore.
Net profit for FY26 stood at Rs. 46.96 crore, slightly lower than Rs. 48.41 crore in FY25. The marginal dip in profitability was primarily attributed to a significant jump in finance costs, which nearly doubled to Rs. 80.42 crore in FY26 from Rs. 51.38 crore in FY25, reflecting the company’s aggressive capital deployment into its subsidiary Neogen Ionics Limited. Despite this, the operating margin for FY26 came in at a healthy 17.68%, and the net profit margin was 5.49%.
On the consolidated level, the numbers paint a more sobering picture. Consolidated revenue from operations for FY26 reached Rs. 861.96 crore, with net profit attributable to the group at Rs. 28.75 crore, a significant decline compared to the standalone figure, indicating meaningful losses at the subsidiary level. The three subsidiary companies collectively reported a net loss of Rs. 18.31 crore for FY26, largely driven by pre-revenue expenditure at Neogen Ionics.
The most market-moving disclosure in the board outcome was the revision of project timelines and costs for Neogen Ionics Limited (NIL), the company’s wholly-owned subsidiary focused on battery chemicals, a high-conviction bet on India’s EV and energy storage supply chain.
The Dahej Phase 1 project, originally slated for an earlier commissioning, now has a revised projected cost of Rs. 428 crore with a Scheduled Commercial Operation Date (SCOD) of February 2027. The Pakhajan Phase 2 project has been revised to Rs. 1,367 crore with a SCOD of March 2027, bringing the combined capex to a staggering Rs. 1,795 crore. The company cited “design optimization based on changeover from in-house to Japanese technology” as the key reason for cost and timeline revisions. Encouragingly, the company stated that an equity infusion from a Promoter Group member has already been received, with additional funding from the JV partner planned.
Adding to the financial complexity, Neogen Chemicals also disclosed that the insurance claim process stemming from the devastating fire at its Dahej SEZ plant on March 5, 2025 remains ongoing. While Rs. 140 crore has been received as an on-account payment and Rs. 7.05 crore realized from scrap sales, the outstanding insurance claim receivable as of March 31, 2026 stands at Rs. 188.96 crore, a substantial figure management believes is fully recoverable. The Board also recommended a final dividend of Rs. 1 per equity share for FY26, subject to shareholder approval at the upcoming 37th AGM.
Shares of Neogen Chemicals Limited were trading at Rs. 1,655.70 on May 18, 2026, down 0.55% from the previous close of Rs. 1,664.80. The stock opened at Rs. 1,690 and touched an intraday high of Rs. 1,695 and a low of Rs. 1,647. The company currently has a market capitalization of about Rs. 4,371 crore and trades at a high P/E of 154.32. The stock is part of the ASM-1 surveillance list and is included in the NIFTY Microcap 250 index.
Company Overview
Neogen Chemicals Limited is a Thane-based specialty chemicals manufacturer, primarily serving the pharmaceutical and agrochemical industries through its organolithium and bromine-based chemistry platforms. Through its wholly-owned subsidiary Neogen Ionics Limited, the company is making a strategic push into battery-grade lithium chemicals, positioning itself as a key domestic supplier for India’s fast-growing EV ecosystem.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Neogen Chemicals Posts Strong Q4 FY26; Revenue Surges 22% QoQ to ₹249 Cr appeared first on Trade Brains.